These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19322950)

  • 1. Aromatase inhibitors and arthralgia: a growing pain?
    Murphy C; Hudis CA; Dickler MN
    Oncology (Williston Park); 2008 Nov; 22(12):1424, 1426. PubMed ID: 19322950
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity.
    Gold JM; Burstein HJ
    Oncology (Williston Park); 2008 Nov; 22(12):1416, 1424. PubMed ID: 19322949
    [No Abstract]   [Full Text] [Related]  

  • 3. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
    Henry NL; Giles JT; Stearns V
    Oncology (Williston Park); 2008 Nov; 22(12):1401-8. PubMed ID: 19086600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of oestrogen in the development of joint symptoms?
    Tan AL; Emery P
    Lancet Oncol; 2008 Sep; 9(9):817-8. PubMed ID: 18760239
    [No Abstract]   [Full Text] [Related]  

  • 5. Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Other Than a Placebo Effect?
    Gianni L; Arcangeli V; Tamburini E; Tassinari D
    J Clin Oncol; 2015 Dec; 33(36):4311-2. PubMed ID: 26392100
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
    Hershman DL; Unger JM; Crew KD; Awad D; Dakhil SR; Gralow J; Greenlee H; Lew DL; Minasian LM; Till C; Wade JL; Meyskens FL; Moinpour CM
    J Clin Oncol; 2015 Jun; 33(17):1910-7. PubMed ID: 25940724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Power of the Placebo in Symptom Management.
    Henry NL; Griggs JJ
    J Clin Oncol; 2015 Jun; 33(17):1870-2. PubMed ID: 25940722
    [No Abstract]   [Full Text] [Related]  

  • 8. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
    Din OS; Dodwell D; Wakefield RJ; Coleman RE
    Breast Cancer Res Treat; 2010 Apr; 120(3):525-38. PubMed ID: 20157776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to L. Gianni et al.
    Hershman DL; Unger JM
    J Clin Oncol; 2015 Dec; 33(36):4312. PubMed ID: 26392106
    [No Abstract]   [Full Text] [Related]  

  • 10. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
    Gaillard S; Stearns V
    Breast Cancer Res; 2011 Mar; 13(2):205. PubMed ID: 21457526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
    Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
    Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of aromatase inhibitors.
    Pandya N; Morris GJ
    Semin Oncol; 2006 Dec; 33(6):688-95. PubMed ID: 17145349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
    Ingle JN
    Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
    Coleman RE; Bolten WW; Lansdown M; Dale S; Jackisch C; Merkel D; Maass N; Hadji P
    Cancer Treat Rev; 2008 May; 34(3):275-82. PubMed ID: 18082328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological therapies can relieve aromatase inhibitor-related joint symptoms in breast cancer survivors.
    Zhang Q; Tang D; Zhao H
    Am J Clin Oncol; 2010 Dec; 33(6):557-60. PubMed ID: 20124972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arthralgia Associated with Autoimmune Abnormalities under Aromatase Inhibitor Therapy: Outcome after Cessation of Treatment.
    Laroche M; Seniow M; Roché H; Ruyssen-Witrand A
    J Rheumatol; 2016 Oct; 43(10):1945-1946. PubMed ID: 27698110
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
    Borrie AE; Kim RB
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):149-156. PubMed ID: 27635473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitor-associated arthralgias.
    Chlebowski RT
    J Clin Oncol; 2009 Oct; 27(30):4932-4. PubMed ID: 19752332
    [No Abstract]   [Full Text] [Related]  

  • 20. Getting a grip on aromatase inhibitor-associated arthralgias.
    Hershman DL
    J Clin Oncol; 2008 Jul; 26(19):3120-1. PubMed ID: 18474872
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.